Table of Contents

1 Study Coverage

• 1.1 Atropine Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Atropine Market Size Growth Rate by Product
  • 1.4.2 Injection
  • 1.4.3 Drop
  • 1.4.4 Gel
• 1.5 Market by End User
  • 1.5.1 Global Atropine Market Size Growth Rate by End User
  • 1.5.2 Gastrointestinal
  • 1.5.3 Ophthalmology
  • 1.5.4 Other
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Atropine Market Size
  • 2.1.1 Global Atropine Revenue 2014-2025
  • 2.1.2 Global Atropine Sales 2014-2025
• 2.2 Atropine Growth Rate by Regions
  • 2.2.1 Global Atropine Sales by Regions
  • 2.2.2 Global Atropine Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Atropine Sales by Manufacturers
  • 3.1.1 Atropine Sales by Manufacturers
  • 3.1.2 Atropine Sales Market Share by Manufacturers
  • 3.1.3 Global Atropine Market Concentration Ratio (CR5 and HHI)
• 3.2 Atropine Revenue by Manufacturers
  • 3.2.1 Atropine Revenue by Manufacturers (2014-2019)
  • 3.2.2 Atropine Revenue Share by Manufacturers (2014-2019)
• 3.3 Atropine Price by Manufacturers
• 3.4 Atropine Manufacturing Base Distribution, Product Types
  • 3.4.1 Atropine Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Atropine Product Type
  • 3.4.3 Date of International Manufacturers Enter into Atropine Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Atropine Sales by Product
• 4.2 Global Atropine Revenue by Product
• 4.3 Atropine Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Atropine Breakdown Data by End User

6 North America

• 6.1 North America Atropine by Countries
  • 6.1.1 North America Atropine Sales by Countries
  • 6.1.2 North America Atropine Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Atropine by Product
• 6.3 North America Atropine by End User

7 Europe

• 7.1 Europe Atropine by Countries
  • 7.1.1 Europe Atropine Sales by Countries
  • 7.1.2 Europe Atropine Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Atropine by Product
• 7.3 Europe Atropine by End User

8 Asia Pacific

• 8.1 Asia Pacific Atropine by Countries
  • 8.1.1 Asia Pacific Atropine Sales by Countries
  • 8.1.2 Asia Pacific Atropine Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Atropine by Product
• 8.3 Asia Pacific Atropine by End User

9 Central & South America

• 9.1 Central & South America Atropine by Countries
  • 9.1.1 Central & South America Atropine Sales by Countries
  • 9.1.2 Central & South America Atropine Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Atropine by Product
• 9.3 Central & South America Atropine by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Atropine by Countries
  • 10.1.1 Middle East and Africa Atropine Sales by Countries
  • 10.1.2 Middle East and Africa Atropine Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Atropine by Product
• 10.3 Middle East and Africa Atropine by End User

11 Company Profiles

• 11.1 C²PHARMA
  • 11.1.1 C²PHARMA Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 C²PHARMA Atropine Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 C²PHARMA Atropine Products Offered
  • 11.1.5 C²PHARMA Recent Development
• 11.2 RESONANCE LABORATORIES
  • 11.2.1 RESONANCE LABORATORIES Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 RESONANCE LABORATORIES Atropine Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 RESONANCE LABORATORIES Atropine Products Offered
  • 11.2.5 RESONANCE LABORATORIES Recent Development
• 11.3 ROLABO OUTSOURCING
  • 11.3.1 ROLABO OUTSOURCING Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 ROLABO OUTSOURCING Atropine Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 ROLABO OUTSOURCING Atropine Products Offered
  • 11.3.5 ROLABO OUTSOURCING Recent Development
• 11.4 Minsheng Group
  • 11.4.1 Minsheng Group Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 Minsheng Group Atropine Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 Minsheng Group Atropine Products Offered
  • 11.4.5 Minsheng Group Recent Development
• 11.5 CR Double-Crane
  • 11.5.1 CR Double-Crane Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 CR Double-Crane Atropine Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 CR Double-Crane Atropine Products Offered
  • 11.5.5 CR Double-Crane Recent Development
• 11.6 HENAN PURUI
  • 11.6.1 HENAN PURUI Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 HENAN PURUI Atropine Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 HENAN PURUI Atropine Products Offered
  • 11.6.5 HENAN PURUI Recent Development
• 11.7 Albany Molecular Research
  • 11.7.1 Albany Molecular Research Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 Albany Molecular Research Atropine Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 Albany Molecular Research Atropine Products Offered
  • 11.7.5 Albany Molecular Research Recent Development
• 11.8 Alchem International
  • 11.8.1 Alchem International Company Details
  • 11.8.2 Company Business Overview
  • 11.8.3 Alchem International Atropine Sales, Revenue and Gross Margin (2014-2019)
  • 11.8.4 Alchem International Atropine Products Offered
  • 11.8.5 Alchem International Recent Development
• 11.9 SAURAV CHEMICALS
  • 11.9.1 SAURAV CHEMICALS Company Details
  • 11.9.2 Company Business Overview
  • 11.9.3 SAURAV CHEMICALS Atropine Sales, Revenue and Gross Margin (2014-2019)
  • 11.9.4 SAURAV CHEMICALS Atropine Products Offered
  • 11.9.5 SAURAV CHEMICALS Recent Development
• 11.10 Katsura Chemical
  • 11.10.1 Katsura Chemical Company Details
  • 11.10.2 Company Business Overview
  • 11.10.3 Katsura Chemical Atropine Sales, Revenue and Gross Margin (2014-2019)
  • 11.10.4 Katsura Chemical Atropine Products Offered
  • 11.10.5 Katsura Chemical Recent Development
• 11.11 Hangzhou Vega
• 11.12 Wuhan senwayer century

12 Future Forecast

• 12.1 Atropine Market Forecast by Regions
  • 12.1.1 Global Atropine Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Atropine Revenue Forecast by Regions 2019-2025
• 12.2 Atropine Market Forecast by Product
  • 12.2.1 Global Atropine Sales Forecast by Product 2019-2025
  • 12.2.2 Global Atropine Revenue Forecast by Product 2019-2025
• 12.3 Atropine Market Forecast by End User
• 12.4 North America Atropine Forecast
• 12.5 Europe Atropine Forecast
• 12.6 Asia Pacific Atropine Forecast
• 12.7 Central & South America Atropine Forecast
• 12.8 Middle East and Africa Atropine Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Atropine Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details

Atropine is a medication to treat certain types of nerve agent and pesticide poisonings as well as some types of slow heart rate and to decrease saliva production during surgery. It is typically given intravenously or by injection into a muscle. Eye drops are also available which are used to treat uveitis and early amblyopia. The intravenous solution usually begins working within a minute and lasts half an hour to an hour. Large doses may be required to treat some poisonings.
Atropine is a medication to treat certain types of nerve agent and pesticide poisonings as well as some types of slow heart rate and to decrease saliva production during surgery. It is typically given intravenously or by injection into a muscle. Eye drops are also available which are used to treat uveitis and early amblyopia. The intravenous solution usually begins working within a minute and lasts half an hour to an hour. Large doses may be required to treat some poisonings.

Atropine industry is relatively fragmented, manufacturers are mostly in the North America, Europe and Asia, and China market production volume accounted for more than 25.43% of the total production volume of global Atropine in 2017. C²PHARMA is the world leading manufacturer in global Atropine market with the market share of 9.19%, in terms of revenue, followed by RESONANCE LABORATORIES, ROLABO OUTSOURCING, Minsheng Group and CR Double-Crane.

Compared to 2016, Atropine market decreased revenue by 5.69 percent to $549.60 million worldwide in 2017 from $582.76 million in 2016. As for the volume segment, global Atropine production decreased to 3862.8 Kg from 4247.4 Kg in 2013. Due to low prices, small profit margins and a relatively narrow market, many companies have abandoned production of atropine, and a shortage of atropine has appeared in the market. This is the result of long-term effects of market behavior.

The average price of Atropine will fall further. The product average price declined in the past few years due to its cheap drug properties, and the average price will keep this trend in the few future years due to market vicious circle.

The global Atropine market is valued at 550 million US$ in 2018 and will reach 480 million US$ by the end of 2025, growing at a CAGR of -1.7% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Atropine market based on company, product type, end user and key regions.

This report studies the global market size of Atropine in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Atropine in these regions.
This research report categorizes the global Atropine market by top players/brands, region, type and end user. This report also studies the global Atropine market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
C²PHARMA
RESONANCE LABORATORIES
ROLABO OUTSOURCING
Minsheng Group
CR Double-Crane
HENAN PURUI
Albany Molecular Research
Alchem International
SAURAV CHEMICALS
Katsura Chemical
Hangzhou Vega
Wuhan senwayer century

Market size by Product
Injection
Drop
Gel
Market size by End User
Gastrointestinal
Ophthalmology
Other

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Atropine market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Atropine market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Atropine companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Atropine submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Atropine are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Atropine market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.